MIRUM PHARMACEUTICALS, INC.
6.80%
4,108,404
1759425
604749101
Jan 22, 2026
Jan 27, 2026, 04:12 PM
Reporting Persons (17)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Patrick J. Heron | Individual | 6.80% | 4,108,404 | 82,482 | 4,025,922 |
| James N. Topper | Individual | 6.70% | 4,025,922 | 0 | 4,025,922 |
| FHMLS IX, L.L.C. | Other | 5.90% | 3,566,912 | 0 | 3,566,912 |
| Frazier Life Sciences IX, L.P. | Partnership | 5.90% | 3,566,912 | 0 | 3,566,912 |
| FHMLS IX, L.P. | Partnership | 5.90% | 3,566,912 | 0 | 3,566,912 |
| Frazier Life Sciences Public Fund, L.P. | Partnership | 4.20% | 2,514,947 | 0 | 2,514,947 |
| FHMLSP, L.P. | Partnership | 4.20% | 2,514,947 | 0 | 2,514,947 |
| FHMLSP, L.L.C. | Other | 4.20% | 2,514,947 | 0 | 2,514,947 |
| FHMLS XI, L.L.C. | Other | 1.80% | 1,075,884 | 0 | 1,075,884 |
| Frazier Life Sciences XI, L.P. | Partnership | 1.80% | 1,075,884 | 0 | 1,075,884 |
| FHMLS XI, L.P. | Partnership | 1.80% | 1,075,884 | 0 | 1,075,884 |
| Frazier Life Sciences X, L.P. | Partnership | 0.80% | 459,010 | 0 | 459,010 |
| FHMLS X, L.P. | Partnership | 0.80% | 459,010 | 0 | 459,010 |
| FHMLS X, L.L.C. | Other | 0.80% | 459,010 | 0 | 459,010 |
| FHMLS XII, L.L.C. | Other | 0.10% | 62,931 | 0 | 62,931 |
| Frazier Life Sciences XII, L.P. | Partnership | 0.10% | 62,931 | 0 | 62,931 |
| FHMLS XII, L.P. | Partnership | 0.10% | 62,931 | 0 | 62,931 |
Disclosure Items (7)
Common Stock, par value $0.0001 per share
MIRUM PHARMACEUTICALS, INC.
989 E Hillsdale Blvd., Suite 300, FOSTER CITY, CA, 94404
The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences IX, L.P. ("FLS IX") FHMLS IX, L.P. FHMLS IX, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron" and together with Topper, the "Members")
Item 2(c) is hereby amended and restated in its entirety to read as follows: FLS IX is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS IX, L.P. is to serve as general partner of FLS IX. The sole business of FHMLS IX, L.L.C. is to serve as general partner of FHMLS IX, L.P. FLS X is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS X, L.P. is to serve as general partner of FLS IX. The sole business of FHMLS X, L.L.C. is to serve as general partner of FHMLS X, L.P. FLSPF is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLSP, L.P. is to serve as general partner of FLSPF. The sole business of FHMLSP, L.L.C. is to serve as general partner of FHMLSP, L.P. FLS XI is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XI, L.P. is to serve as general partner of FLS XI. The sole business of FHMLS XI, L.L.C. is to serve as general partner of FHMLS XI, L.P. FLS XII is a venture capital fund concentrating in life sciences and related fields. The sole business of FHMLS XII, L.P. is to serve as general partner of FLS XII. The sole business of FHMLS XII, L.L.C. is to serve as general partner of FHMLS XII, L.P. The principal business of the Members is to manage FLS IX, FHMLS IX, L.P., FHMLS IX, L.L.C., FLS X, FHMLS X, L.P., FHMLS X, L.L.C., FLSPF, FHMLSP, L.P., FHMLSP, L.L.C., FLS XI, FHMLS XI, L.P., FHMLS XI, L.L.C., FLS XII, FHMLS XII, L.P., FHMLS XII, L.L.C. and a number of affiliated partnerships with similar businesses.
Item 2(f) is hereby amended and restated in its entirety to read as follows: Entities: FLS IX - Delaware, U.S.A. FHMLS IX, L.P. - Delaware, U.S.A. FHMLS IX, L.L.C. - Delaware, U.S.A. FLS X - Delaware, U.S.A. FHMLS X, L.P. - Delaware, U.S.A. FHMLS X, L.L.C. - Delaware, U.S.A. FLSPF - Delaware, U.S.A. FHMLSP, L.P. - Delaware, U.S.A. FHMLSP, L.L.C. - Delaware, U.S.A. FLS XI - Delaware, U.S.A. FHMLS XI, L.P. - Delaware, U.S.A. FHMLS XI, L.L.C. - Delaware, U.S.A. FLS XII - Delaware, U.S.A. FHMLS XII, L.P. - Delaware, U.S.A. FHMLS XII, L.L.C.- Delaware, U.S.A. Individuals: Topper - United States Citizen Heron - United States Citizen
Item 3 of the Schedule 13D is hereby amended to incorporate Item 5(c) hereof and to replace the last paragraph with the following: The working capital of FLS IX, FLS X, FLSPF, FLS XI and FLS XII was the source of the funds for the purchase of the FLS IX Shares, the FLS X Shares, the FLSPF Shares, the FLS XI Shares and the FLS XI Shares. No part of the purchase price of the FLS IX Shares, the FLS X Shares, the FLSPF Shares, the FLS XI Shares or the FLS XII Shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the FLS IX Shares, the FLS X Shares, the FLSPF Shares, the FLS XI Shares and the FLS XII Shares.
The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5. FLSPF directly holds 2,514,947 shares of Common Stock of the Issuer (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS IX directly holds 3,566,912 shares of Common Stock of the Issuer (the "FLS IX Shares"). FHMLS IX, L.P. is the general partner of FLS IX and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Heron and Topper are the members of FHMLS IX, L.L.C. and therefore share voting and investment power over the FLS IX Shares. FLS X directly holds 459,010 shares of Common Stock of the Issuer (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares. FLS XI directly holds 1,075,884 shares of Common Stock of the Issuer (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 62,931 shares of Common Stock of the Issuer (the "FLS XI Shares"). FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, FLSPF holds Warrants to purchase 536,412 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.
Except as set forth on Exhibit 10.1 of this Schedule 13D, none of the Reporting Persons has effected any transactions relating to the Ordinary Shares during the past 60 days.
Item 4 is hereby amended and restated in its entirety to read as follows: No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the FLS IX Shares, the FLS X Shares, the FLSPF Shares, the FLS XI Shares or the FLS XII Shares beneficially owned by any of the Reporting Persons, other than the respective limited partners, general partners, members and/or beneficiaries of such Reporting Persons.
Registration Rights Agreement Pursuant to the terms of a Registration Rights Agreement with the Issuer dated December 7, 2025 (the "Registration Rights Agreement"), certain holders of the Issuer's Common Stock, including FLSPF, FLS X, FLS XI, FLS XII, are entitled to rights with respect to the registration under the Securities Act of 1933, as amended, of the shares of Common Stock or the shares of Common Stock issuable upon exercise of the pre-funded warrants that were purchased on January 23, 2026 (the "Registrable Securities"). Under the terms of the Registration Rights Agreement, the Issuer has agreed to prepare and file a registration statement with the SEC to register for resale the Registrable Securities. The Company has agreed to be responsible for all fees and expenses incurred in connection with the registration of the Registrable Securities. Other than as described in this Schedule 13D, to the best of the Reporting Persons' knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.
Exhibit 10.1 Transactions Relating to the Common Stock of the Issuer During the Past Sixty (60) Days Exhibit 10.2 Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025). Exhibit 24.1 Power of Attorney Exhibit 99.1 Joint Filing Agreement